Biotech Fades After ASCO Abstract Rally
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of the biotech ETFs. Large cap...
ASCO Abstracts Week: Biotech Trends and Hot Stocks
Biotech Trends: Immuno-Oncology Stocks Trending Strong Await ASCO Meeting on June 2 Prices as of Monday 11:45A with NASDAQ up 0.73% FBT $106.75 up 0.2%, IBB flat at $290.64, XBI at $69.33 up 0.3% Here is a selection of biotech trending stocks that have had significant moves or released ASCO...
Biotechs Mired in a Trading Range: Breakout Delayed…Update-3
Update-3...ASCO Movers Today 5/18: IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the "Trump Trade" (industrials and materials). Mid-caps and small caps were very strong. Large Caps: MRK up 1.35%,REGN...
Rayno Diagnostics and Tools: Hologic Beats Q1 Sales and EPS
Hologic, Inc. (HOLX) Beats: Revenues Increased 3.2% and GAAP diluted Earnings Increased 666.7% Compared to Prior Year Period (fiscal Q2) The base business grew 5.4% lead by molecular diagnostics, surgical and international franchises.Restructuring completed. The newly acquired Cynosure business...
Large Cap Biopharmaceutical Valuations: Q1 2017
May 8, 2017 Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics: Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%....